Evidence map›Paper›PMID 25911465›Full record

ArticleStem cells translational medicine2015

Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele.

Aijun Wang, Erin G Brown, Lee Lankford, Benjamin A Keller, Christopher D Pivetti, Nicole A Sitkin, Michael S Beattie, Jacqueline C Bresnahan, Diana L Farmer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Placenta as a source of autologous graft in postnatal correction of myelomeningocele.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Aijun WangSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA aawang@ucdavis.edu.
Erin G BrownSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Lee LankfordSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Benjamin A KellerSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Christopher D PivettiSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Nicole A SitkinSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Michael S BeattieSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Jacqueline C BresnahanSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Diana L FarmerSurgical Bioengineering Laboratory, Department of Surgery, University of California, Davis, Health System, Sacramento, California, USA; Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
University of California, Davis · USUniversity of California, San Francisco · US

Funding

Mechanisms of secondary injury after SCIR01NS038079 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BEATTIE, MICHAEL S, BRESNAHAN, JACQUELINE C · 1999 to 2015
$5.8M
6 · The paper itself

Abstract

unlabelledMyelomeningocele (MMC)-commonly known as spina bifida-is a congenital birth defect that causes lifelong paralysis, incontinence, musculoskeletal deformities, and severe cognitive disabilities. The recent landmark Management of Myelomeningocele Study (MOMS) demonstrated for the first time in humans that in utero surgical repair of the MMC defect improves lower limb motor function, suggesting a capacity for improved neurologic outcomes in this disorder. However, functional recovery was incomplete, and 58% of the treated children were unable to walk independently at 30 months of age. In the present study, we demonstrate that using early gestation human placenta-derived mesenchymal stromal cells (PMSCs) to augment in utero repair of MMC results in significant and consistent improvement in neurologic function at birth in the rigorous fetal ovine model of MMC. In vitro, human PMSCs express characteristic MSC markers and trilineage differentiation potential. Protein array assays and enzyme-linked immunosorbent assay show that PMSCs secrete a variety of immunomodulatory and angiogenic cytokines. Compared with adult bone marrow MSCs, PMSCs secrete significantly higher levels of brain-derived neurotrophic factor and hepatocyte growth factor, both of which have known neuroprotective capabilities. In vivo, functional and histopathologic analysis demonstrated that human PMSCs mediate a significant, clinically relevant improvement in motor function in MMC lambs and increase the preservation of large neurons within the spinal cord. These preclinical results in the well-established fetal ovine model of MMC provide promising early support for translating in utero stem cell therapy for MMC into clinical application for patients. SIGNIFICANCE: This study presents placenta-derived mesenchymal stromal cell (PMSC) treatment as a potential therapy for myelomeningocele (MMC). Application of PMSCs can augment current in utero surgical repair in the well-established and rigorously applied fetal lamb model of MMC. Treatment with human PMSCs significantly and dramatically improved neurologic function and preserved spinal cord neuron density in experimental animals. Sixty-seven percent of the PMSC-treated lambs were able to ambulate independently, with two exhibiting no motor deficits whatsoever. In contrast, none of the lambs treated with the vehicle alone were capable of ambulation. The locomotor rescue demonstrated in PMSC-treated lambs indicates great promise for future clinical trials to improve paralysis in children afflicted with MMC.

Indexed as

Mesenchymal Stem Cell TransplantationAdultAllograftsAnimalsDisease Models, AnimalFemaleHumansMeningomyeloceleMesenchymal Stem CellsPlacentaPregnancySheepCellular therapyFetal stem cellsMesenchymal stem cellsPlacentaStem cell

Identifiers

PMID25911465
PMCPMC4449103
OpenAlexW2131696152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.